Drug reference

Lixisenatide

GLP-1 Receptor Agonist · Antidiabetic, Anti-obesity

GLP-1 Receptor AgonistAntidiabetic, Anti-obesity

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

2 major

SEVERE in our sources

PREGNANCY

[unlicensed indication]. h Long-term beneﬁt or superiority

FDA category + note

Top interactions

BexaroteneSevereDatabaseDDInter
GatifloxacinSevereDatabaseDDInter

Mechanism

Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It activates GLP-1 receptors found on β cells, in the nervous system, heart, kidney, lung, and GI mucosa. This action activates the cAMP-PKA pathway and other signaling cascades. The ultimate effect in β cells is increased insulin biosynthesis and secretion in a glucose-dependent manner.

Indications

Type 2 diabetes (as combination therapy when other treatment options fail)ObesityTreatment of diabetic patients (type 2 diabetes)

Dosing

Adult: plasma proteins. Liraglutide is supplied in a pen injector that delivers 0.6, 1.2, or 1.8 mg of drug; the low dose is for treatment initiation and generally advanced to the two higher doses based on clinical. sitagliptin is 100 mg once daily. The recommended dose of. saxagliptin is 5 mg once daily..…